PATHWAY-2: spironolactone for resistant hypertension.
Centre for Evidence Based Medicine, Department of Primary Care Health Sciences, Oxford OX2 6NW, UK.
Aaron
A
Dale
Centre for Evidence Based Medicine, Department of Primary Care Health Sciences, Oxford OX2 6NW, UK.
Philip
P
Hartley
Centre for Evidence Based Medicine, Department of Primary Care Health Sciences, Oxford OX2 6NW, UK. Electronic address: compare-team@ebmdatalab.net.
Ben
B
Goldacre
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D017298:Bisoprolol / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D013148:Spironolactone / Q000627:therapeutic use*
D058668:Adrenergic alpha-1 Receptor Antagonists; D058671:Adrenergic beta-1 Receptor Antagonists; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D017292:Doxazosin; D017298:Bisoprolol